{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:28:32Z","timestamp":1785241712237,"version":"3.55.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T00:00:00Z","timestamp":1600128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The control of schistosomiasis has been centered to date on a single drug, praziquantel, with shortcomings including treatment failure, reinfection, and emergence of drug resistance. Drug repurposing, combination therapy or nanotechnology were explored to improve antischistosomal treatment. The aim of the present study was to utilize a novel combination of the three strategies to improve the therapeutic profile of praziquantel. This was based on a fixed-dose nanocombination of praziquantel and miltefosine, an antischistosomal repurposing candidate, co-loaded at reduced doses into lipid nanocapsules, for single dose oral therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Two nanocombinations were prepared to provide 250\u00a0mg praziquantel-20\u00a0mg miltefosine\/kg (higher fixed-dose) or 125\u00a0mg praziquantel-10\u00a0mg miltefosine\/kg (lower fixed-dose), respectively. Their antischistosomal efficacy in comparison with a non-treated control and their praziquantel or miltefosine singly loaded counterparts was assessed in murine schistosomiasis mansoni. A single oral dose of either formulation was administered on the initial day of infection, and on days 21 and 42 post-infection. Scanning electron microscopic, parasitological, and histopathological studies were used for assessment. Preclinical data were subjected to analysis of variance and Tukey\u02bcs\n                      <jats:italic>post-hoc<\/jats:italic>\n                      test for pairwise comparisons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Lipid nanocapsules (~\u00a058\u00a0nm) showed high entrapment efficiency of both drugs (&gt;\u00a097%). Compared to singly loaded praziquantel-lipid nanocapsules, the higher nanocombination dose showed a significant increase in antischistosomal efficacy in terms of statistically significant decrease in mean worm burden, particularly against invasive and juvenile worms, and amelioration of hepatic granulomas (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0\u2264\u00a00.05). In addition, scanning electron microscopy examination showed extensive dorsal tegumental damage with noticeable deposition of nanostructures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The therapeutic profile of praziquantel could be improved by a novel multiple approach integrating drug repurposing, combination therapy and nanotechnology. Multistage activity and amelioration of liver pathology could be achieved by a new praziquantel-miltefosine fixed-dose nanocombination providing 250\u00a0mg praziquantel-20\u00a0mg miltefosine\/kg. To the best of our knowledge, this is the first report of a fixed-dose nano-based combinatorial therapy for schistosomiasis mansoni. Further studies are needed to document the nanocombination safety and explore its prophylactic activity and potential to hinder the onset of resistance to the drug components.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-020-04346-1","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T10:03:53Z","timestamp":1600164233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni"],"prefix":"10.1186","volume":"13","author":[{"given":"Maha M.","family":"Eissa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat Z.","family":"El-Azzouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-8113","authenticated-orcid":false,"given":"Labiba K.","family":"El-Khordagui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany","family":"Abdel Bary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham M.","family":"El-Moslemany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Abdel Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"4346_CR1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-030-18616-6_3","volume-title":"Digenetic trematodes","author":"PT LoVerde","year":"2019","unstructured":"LoVerde PT. Schistosomiasis. In: Toledo R, Fried B, editors. Digenetic trematodes. Cham: Springer International Publishing; 2019. p. 45\u201370."},{"key":"4346_CR2","doi-asserted-by":"crossref","first-page":"e0006144","DOI":"10.1371\/journal.pntd.0006144","volume":"12","author":"DN Osakunor","year":"2018","unstructured":"Osakunor DN, Woolhouse ME, Mutapi F. Paediatric schistosomiasis: what we know and what we need to know. PLoS Negl Trop Dis. 2018;12:e0006144.","journal-title":"PLoS Negl Trop Dis"},{"key":"4346_CR3","doi-asserted-by":"crossref","first-page":"e0006902","DOI":"10.1371\/journal.pntd.0006902","volume":"12","author":"KM Wall","year":"2018","unstructured":"Wall KM, Kilembe W, Vwalika B, Dinh C, Livingston P, Lee YM, et al. Schistosomiasis is associated with incident HIV transmission and death in Zambia. PLoS Negl Trop Dis. 2018;12:e0006902.","journal-title":"PLoS Negl Trop Dis"},{"key":"4346_CR4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/HMER.S155962","volume":"11","author":"HH Omar","year":"2019","unstructured":"Omar HH. Impact of chronic schistosomiasis and HBV\/HCV co-infection on the liver: current perspectives. Hepat Med. 2019;11:131\u20136.","journal-title":"Hepat Med"},{"key":"4346_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3697216","author":"E Woldegerima","year":"2019","unstructured":"Woldegerima E, Bayih AG, Tegegne Y, Aemero M, Jejaw Zeleke A. Prevalence and reinfection rates of Schistosoma mansoni and praziquantel efficacy against the parasite among primary school children in Sanja town, Northwest Ethiopia. J Parasitol Res. 2019. https:\/\/doi.org\/10.1155\/2019\/3697216.","journal-title":"J Parasitol Res"},{"key":"4346_CR6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-3156.2009.02234.x","volume":"14","author":"CL Black","year":"2009","unstructured":"Black CL, Steinauer ML, Mwinzi PN, Evan Secor W, Karanja DM, Colley DG. Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya. Trop Med Int Health. 2009;14:450\u20137.","journal-title":"Trop Med Int Health"},{"key":"4346_CR7","doi-asserted-by":"crossref","first-page":"e02582-16","DOI":"10.1128\/AAC.02582-16","volume":"61","author":"N Vale","year":"2017","unstructured":"Vale N, Gouveia MJ, Rinaldi G, Brindley PJ, Gartner F, Correia da Costa JM. Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother. 2017;61:e02582-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"4346_CR8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/1062936X.2019.1607898","volume":"30","author":"VBR da Silva","year":"2019","unstructured":"da Silva VBR, Boucherle B, El-Methni J, Hoffmann B, da Silva AL, Fortune A, et al. Could we expect new praziquantel derivatives? A meta pharmacometrics\/pharmacoinformatics analysis of all antischistosomal praziquantel derivatives found in the literature. SAR QSAR Environ Res. 2019;30:383\u2013401.","journal-title":"SAR QSAR Environ Res"},{"key":"4346_CR9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/acsinfecdis.9b00354","volume":"6","author":"H Lyu","year":"2020","unstructured":"Lyu H, Petukhov PA, Banta PR, Jadhav A, Lea W, Cheng Q, et al. Characterization of lead compounds targeting the selenoprotein thioredoxin glutathione reductase for treatment of schistosomiasis. ACS Infect Dis. 2020;6:393\u2013405.","journal-title":"ACS Infect Dis"},{"key":"4346_CR10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1021\/acsinfecdis.9b00224","volume":"6","author":"F Saccoccia","year":"2020","unstructured":"Saccoccia F, Brindisi M, Gimmelli R, Relitti N, Guidi A, Saraswati AP, et al. Screening and phenotypical characterization of Schistosoma mansoni Histone deacetylase 8 (SmHDAC8) inhibitors as multistage antischistosomal agents. ACS Infect Dis. 2020;6:100\u201313.","journal-title":"ACS Infect Dis"},{"key":"4346_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exppara.2019.02.010","volume":"199","author":"MM Abou El Dahab","year":"2019","unstructured":"Abou El Dahab MM, Shahat SM, Mahmoud SSM, Mahana NA. In vitro effect of curcumin on Schistosoma species viability, tegument ultrastructure and egg hatchability. Exp Parasitol. 2019;199:1\u20138.","journal-title":"Exp Parasitol"},{"key":"4346_CR12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1017\/S0022149X18000317","volume":"93","author":"EVN Beshay","year":"2019","unstructured":"Beshay EVN, Rady AA, Afifi AF, Mohamed AH. Schistosomicidal, antifibrotic and antioxidant effects of Cucurbita pepo L. seed oil and praziquantel combined treatment for Schistosoma mansoni infection in a mouse model. J Helminthol. 2019;93:286\u201394.","journal-title":"J Helminthol"},{"key":"4346_CR13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpara.2010.09.010","volume":"41","author":"MM Eissa","year":"2011","unstructured":"Eissa MM, El-Azzouni MZ, Amer EI, Baddour NM. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int J Parasitol. 2011;41:235\u201342.","journal-title":"Int J Parasitol"},{"key":"4346_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/ph11010015","volume":"11","author":"MJ Gouveia","year":"2018","unstructured":"Gouveia MJ, Brindley PJ, Gartner F, Costa J, Vale N. Drug repurposing for schistosomiasis: combinations of drugs or biomolecules. Pharmaceuticals. 2018;11:15.","journal-title":"Pharmaceuticals"},{"key":"4346_CR15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1756-3305-4-73","volume":"4","author":"MM Eissa","year":"2011","unstructured":"Eissa MM, El Bardicy S, Tadros M. Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy. Parasit Vectors. 2011;4:73.","journal-title":"Parasit Vectors"},{"key":"4346_CR16","doi-asserted-by":"crossref","first-page":"e0141788","DOI":"10.1371\/journal.pone.0141788","volume":"10","author":"MM Eissa","year":"2015","unstructured":"Eissa MM, El-Moslemany RM, Ramadan AA, Amer EI, El-Azzouni MZ, El-Khordagui LK. Miltefosine lipid nanocapsules for single dose oral treatment of schistosomiasis mansoni: a preclinical study. PLoS ONE. 2015;10:e0141788.","journal-title":"PLoS ONE"},{"key":"4346_CR17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.actatropica.2016.03.038","volume":"159","author":"RM El-Moslemany","year":"2016","unstructured":"El-Moslemany RM, Eissa MM, Ramadan AA, El-Khordagui LK, El-Azzouni MZ. Miltefosine lipid nanocapsules: intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni. Acta Trop. 2016;159:142\u20138.","journal-title":"Acta Trop"},{"key":"4346_CR18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.arcontrol.2019.08.001","volume":"48","author":"ABC Santos-Valle","year":"2019","unstructured":"Santos-Valle ABC, Souza GR, Paes CQ, Miyazaki T, Silva AH, Altube MJ, et al. Nanomedicine strategies for addressing major needs in neglected tropical diseases. Annu Rev Control. 2019;48:423\u201341.","journal-title":"Annu Rev Control"},{"key":"4346_CR19","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1080\/10717544.2019.1692968","volume":"26","author":"Y Sun","year":"2019","unstructured":"Sun Y, Chen D, Pan Y, Qu W, Hao H, Wang X, et al. Nanoparticles for antiparasitic drug delivery. Drug Deliv. 2019;26:1206\u201321.","journal-title":"Drug Deliv"},{"key":"4346_CR20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s12639-019-01106-6","volume":"43","author":"AEM Labib El Gendy","year":"2019","unstructured":"Labib El Gendy AEM, Mohammed FA, Abdel-Rahman SA, Shalaby TIA, Fathy GM, Mohammad SM, et al. Effect of nanoparticles on the therapeutic efficacy of praziquantel against Schistosoma mansoni infection in murine models. J Parasit Dis. 2019;43:416\u201325.","journal-title":"J Parasit Dis"},{"key":"4346_CR21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13071-019-3563-z","volume":"12","author":"A Radwan","year":"2019","unstructured":"Radwan A, El-Lakkany NM, William S, El-Feky GS, Al-Shorbagy MY, Saleh S, et al. A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection. Parasites Vectors. 2019;12:304.","journal-title":"Parasites Vectors"},{"key":"4346_CR22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00436-018-6132-z","volume":"118","author":"HS Zoghroban","year":"2019","unstructured":"Zoghroban HS, El-Kowrany SI, Aboul Asaad IA, El Maghraby GM, El-Nouby KA, Abd Elazeem MA. Niosomes for enhanced activity of praziquantel against Schistosoma mansoni: in vivo and in vitro evaluation. Parasitol Res. 2019;118:219\u201334.","journal-title":"Parasitol Res"},{"key":"4346_CR23","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1007\/s00436-019-06475-8","volume":"118","author":"GM Tawfeek","year":"2019","unstructured":"Tawfeek GM, Baki MHA, Ibrahim AN, Mostafa MAH, Fathy MM, Diab M. Enhancement of the therapeutic efficacy of praziquantel in murine Schistosomiasis mansoni using silica nanocarrier. Parasitol Res. 2019;118:3519\u201333.","journal-title":"Parasitol Res"},{"key":"4346_CR24","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.2147\/IJN.S167285","volume":"13","author":"RO Amara","year":"2018","unstructured":"Amara RO, Ramadan AA, El-Moslemany RM, Eissa MM, El-Azzouni MZ, El-Khordagui LK. Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting. Int J Nanomed. 2018;13:4493\u2013505.","journal-title":"Int J Nanomed"},{"key":"4346_CR25","doi-asserted-by":"crossref","first-page":"119653","DOI":"10.1016\/j.biomaterials.2019.119653","volume":"230","author":"D Carradori","year":"2020","unstructured":"Carradori D, Labrak Y, Miron VE, Saulnier P, Eyer J, Preat V, et al. Retinoic acid-loaded NFL-lipid nanocapsules promote oligodendrogenesis in focal white matter lesion. Biomaterials. 2020;230:119653.","journal-title":"Biomaterials"},{"key":"4346_CR26","doi-asserted-by":"crossref","first-page":"105215","DOI":"10.1016\/j.actatropica.2019.105215","volume":"201","author":"J Fabbri","year":"2020","unstructured":"Fabbri J, Espinosa JP, Pensel PE, Medici SK, Gamboa GU, Benoit JP, et al. Do albendazole-loaded lipid nanocapsules enhance the bioavailability of albendazole in the brain of healthy mice? Acta Trop. 2020;201:105215.","journal-title":"Acta Trop"},{"key":"4346_CR27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2009.04.026","volume":"379","author":"NT Huynh","year":"2009","unstructured":"Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm. 2009;379:201\u20139.","journal-title":"Int J Pharm"},{"key":"4346_CR28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.exppara.2019.02.002","volume":"198","author":"GV Ullio Gamboa","year":"2019","unstructured":"Ullio Gamboa GV, Pensel PE, Elissondo MC, Sanchez Bruni SF, Benoit JP, Palma SD, et al. Albendazole-lipid nanocapsules: optimization, characterization and chemoprophylactic efficacy in mice infected with Echinococcus granulosus. Exp Parasitol. 2019;198:79\u201386.","journal-title":"Exp Parasitol"},{"key":"4346_CR29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1049\/iet-nbt.2018.0006","volume":"12","author":"J Varshosaz","year":"2018","unstructured":"Varshosaz J, Taymouri S, Jahanian-Najafabadi A, Alizadeh A. Efavirenz oral delivery via lipid nanocapsules: formulation, optimisation, and ex-vivo gut permeation study. IET Nanobiotechnol. 2018;12:795\u2013806.","journal-title":"IET Nanobiotechnol"},{"key":"4346_CR30","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/jcp.29216","volume":"235","author":"A Derakhshani","year":"2020","unstructured":"Derakhshani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati MA, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2020;235:3142\u201356.","journal-title":"J Cell Physiol"},{"key":"4346_CR31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17474124.2020.1715209","volume":"14","author":"A Kawazoe","year":"2020","unstructured":"Kawazoe A, Shitara K. Trifluridine\/tipiracil for the treatment of metastatic gastric cancer. Expert Rev Gastroenterol Hepatol. 2020;14:65\u201370.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"4346_CR32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14787210.2020.1705155","volume":"18","author":"ARM Coates","year":"2020","unstructured":"Coates ARM, Hu Y, Holt J, Yeh P. Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction. Expert Rev Anti Infect Ther. 2020;18:5\u201315.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4346_CR33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4155\/tde.10.13","volume":"1","author":"CM Hu","year":"2010","unstructured":"Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv. 2010;1:323\u201334.","journal-title":"Ther Deliv"},{"key":"4346_CR34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/17425247.2020.1715938","volume":"17","author":"T Al-Attar","year":"2020","unstructured":"Al-Attar T, Madihally SV. Recent advances in the combination delivery of drug for leukemia and other cancers. Expert Opin Drug Deliv. 2020;17:213\u201323.","journal-title":"Expert Opin Drug Deliv"},{"key":"4346_CR35","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","volume":"10","author":"M Zhao","year":"2020","unstructured":"Zhao M, van Straten D, Broekman MLD, Preat V, Schiffelers RM. Nanocarrier-based drug combination therapy for glioblastoma. Theranostics. 2020;10:1355\u201372.","journal-title":"Theranostics"},{"key":"4346_CR36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejps.2018.10.017","volume":"127","author":"P Walvekar","year":"2019","unstructured":"Walvekar P, Gannimani R, Govender T. Combination drug therapy via nanocarriers against infectious diseases. Eur J Pharm Sci. 2019;127:121\u201341.","journal-title":"Eur J Pharm Sci"},{"key":"4346_CR37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10544-020-0476-8","volume":"22","author":"S Pawar","year":"2020","unstructured":"Pawar S, Shende P. 2(2) factorial design-based biocompatible microneedle arrays containing artemether co-loaded with lumefantrine nanoparticles for transepidermal delivery. Biomed Microdevices. 2020;22:19","journal-title":"Biomed Microdevices."},{"key":"4346_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/08982104.2017.1410173","volume":"29","author":"K Shakeel","year":"2019","unstructured":"Shakeel K, Raisuddin S, Ali S, Imam SS, Rahman MA, Jain GK, Ahmad FJ. Development and in vitro\/in vivo evaluation of artemether and lumefantrine co-loaded nanoliposomes for parenteral delivery. J Liposome Res. 2019;29:35\u201343. https:\/\/doi.org\/10.1080\/08982104.2017.1410173.","journal-title":"J Liposome Res."},{"key":"4346_CR39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.actatropica.2017.06.025","volume":"174","author":"F Tomiotto-Pellissier","year":"2017","unstructured":"Tomiotto-Pellissier F, Miranda-Sapla MM, Machado LF, Bortoleti B, Sahd CS, Chagas AF, et al. Nanotechnology as a potential therapeutic alternative for schistosomiasis. Acta Trop. 2017;174:64\u201371.","journal-title":"Acta Trop"},{"key":"4346_CR40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41596-018-0101-y","volume":"14","author":"FC Lombardo","year":"2019","unstructured":"Lombardo FC, Pasche V, Panic G, Endriss Y, Keiser J. Life cycle maintenance and drug-sensitivity assays for early drug discovery in Schistosoma mansoni. Nat Protoc. 2019;14:461\u201381.","journal-title":"Nat Protoc"},{"key":"4346_CR41","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1017\/S0031182000086248","volume":"55","author":"SR Smithers","year":"1965","unstructured":"Smithers SR, Terry RJ. The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms. Parasitology. 1965;55:695\u2013700.","journal-title":"Parasitology"},{"key":"4346_CR42","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/B978-0-12-318880-9.50013-2","volume-title":"Electron microscopy of plant cells","author":"CE Jeffree","year":"1991","unstructured":"Jeffree CE, Read ND. Ambient-and low-temperature scanning electron microscopy. In: Hall JL, Hawes C, editors. Electron microscopy of plant cells. New York: Academic Press; 1991. p. 313\u2013413."},{"key":"4346_CR43","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.pathol.2018.01.004","volume":"50","author":"L Le","year":"2018","unstructured":"Le L, Molehin AJ, Nash S, Sennoune SR, Ahmad G, Torben W, et al. Schistosoma egg-induced liver pathology resolution by Sm-p80-based schistosomiasis vaccine in baboons. Pathology. 2018;50:442\u20139.","journal-title":"Pathology"},{"key":"4346_CR44","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.parint.2012.12.001","volume":"62","author":"JD Chan","year":"2013","unstructured":"Chan JD, Zarowiecki M, Marchant JS. Ca2+ channels and praziquantel: a view from the free world. Parasitol Int. 2013;62:619\u201328.","journal-title":"Parasitol Int"},{"key":"4346_CR45","doi-asserted-by":"crossref","first-page":"18873","DOI":"10.1074\/jbc.AC119.011093","volume":"294","author":"SK Park","year":"2019","unstructured":"Park SK, Gunaratne GS, Chulkov EG, Moehring F, McCusker P, Dosa PI, et al. The anthelmintic drug praziquantel activates a schistosome transient receptor potential channel. J Biol Chem. 2019;294:18873\u201380.","journal-title":"J Biol Chem"},{"key":"4346_CR46","first-page":"1398","volume":"60","author":"B Monge-Maillo","year":"2015","unstructured":"Monge-Maillo B, Lopez-Velez R. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis. 2015;60:1398\u2013404.","journal-title":"Clin Infect Dis"},{"key":"4346_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbamem.2016.10.008","volume":"1859","author":"KS Fernandes","year":"2017","unstructured":"Fernandes KS, de Souza PE, Dorta ML, Alonso A. The cytotoxic activity of miltefosine against Leishmania and macrophages is associated with dynamic changes in plasma membrane proteins. Biochim Biophys Acta Biomembr. 2017;1859:1\u20139.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"4346_CR48","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1128\/AAC.01332-13","volume":"58","author":"RA Moreira","year":"2014","unstructured":"Moreira RA, Mendanha SA, Fernandes KS, Matos GG, Alonso L, Dorta ML, et al. Miltefosine increases lipid and protein dynamics in Leishmania amazonensis membranes at concentrations similar to those needed for cytotoxicity activity. Antimicrob Agents Chemother. 2014;58:3021\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"4346_CR49","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1645\/GE-745R1.1","volume":"92","author":"R El Ridi","year":"2006","unstructured":"El Ridi R, Tallima H. Equilibrium in lung schistosomula sphingomyelin breakdown and biosynthesis allows very small molecules, but not antibody, to access proteins at the host-parasite interface. J Parasitol. 2006;92:730\u20137.","journal-title":"J Parasitol"},{"key":"4346_CR50","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00436-011-2786-5","volume":"110","author":"HG Bertao","year":"2012","unstructured":"Bertao HG, da Silva RA, Padilha RJ, de Azevedo Albuquerque MC, Radis-Baptista G. Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms. Parasitol Res. 2012;110:2465\u201373.","journal-title":"Parasitol Res"},{"key":"4346_CR51","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/infdis\/151.6.1130","volume":"151","author":"SH Xiao","year":"1985","unstructured":"Xiao SH, Catto BA, Webster LT Jr. Effects of praziquantel on different developmental stages of Schistosoma mansoni in vitro and in vivo. J Infect Dis. 1985;151:1130\u20137.","journal-title":"J Infect Dis"},{"key":"4346_CR52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molbiopara.2008.11.007","volume":"164","author":"AD Aragon","year":"2009","unstructured":"Aragon AD, Imani RA, Blackburn VR, Cupit PM, Melman SD, Goronga T, et al. Towards an understanding of the mechanism of action of praziquantel. Mol Biochem Parasitol. 2009;164:57\u201365.","journal-title":"Mol Biochem Parasitol"},{"key":"4346_CR53","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.pt.2019.11.007","volume":"36","author":"B Masi","year":"2020","unstructured":"Masi B, Perles-Barbacaru TA, Bernard M, Viola A. Clinical and preclinical imaging of hepatosplenic schistosomiasis. Trends Parasitol. 2020;36:206\u201326.","journal-title":"Trends Parasitol"},{"key":"4346_CR54","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00436-015-4324-3","volume":"114","author":"W Li-zhi","year":"2015","unstructured":"Li-zhi W, Xin-Sheng Z, Jiang-shan D, Yi W, Bao-an Y. Transdermal praziquantel administration attenuates hepatic granulomatosis in mice infected with Schistosoma japonicum. Parasitol Res. 2015;114:1417\u201324.","journal-title":"Parasitol Res"},{"key":"4346_CR55","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/BF02535556","volume":"22","author":"A Breiser","year":"1987","unstructured":"Breiser A, Kim DJ, Fleer EA, Damenz W, Drube A, Berger M, et al. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids. 1987;22:925\u20136.","journal-title":"Lipids"},{"key":"4346_CR56","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejps.2018.06.002","volume":"121","author":"MD Jimenez-Anton","year":"2018","unstructured":"Jimenez-Anton MD, Garcia-Calvo E, Gutierrez C, Escribano MD, Kayali N, Luque-Garcia JL, et al. Pharmacokinetics and disposition of miltefosine in healthy mice and hamsters experimentally infected with Leishmania infantum. Eur J Pharm Sci. 2018;121:281\u20136.","journal-title":"Eur J Pharm Sci"},{"key":"4346_CR57","first-page":"687","volume":"39","author":"G Morsy","year":"2009","unstructured":"Morsy G. Parasitological and histo-pathological studies on schistosomiasis mansoni infected mice and treated with praziquatel and\/or oltipraz. J Egypt Soc Parasitol. 2009;39:687\u2013701.","journal-title":"J Egypt Soc Parasitol"},{"key":"4346_CR58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0001-706X(00)00067-X","volume":"75","author":"S Xiao","year":"2000","unstructured":"Xiao S, Binggui S, Chollet J, Tanner M. Tegumental changes in 21-day-old Schistosoma mansoni harboured in mice treated with artemether. Acta Trop. 2000;75:341\u20138.","journal-title":"Acta Trop"},{"key":"4346_CR59","first-page":"193","volume":"13","author":"LAM Hegazy","year":"2018","unstructured":"Hegazy LAM, Motiam MHA, Abd El-Aal NF, Ibrahim SM, Mohamed HK. Evaluation of artesunate and praziquantel combination therapy in murine schistosomiasis mansoni. Iran J Parasitol. 2018;13:193\u2013203.","journal-title":"Iran J Parasitol"},{"key":"4346_CR60","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/jac\/dkr178","volume":"66","author":"J Keiser","year":"2011","unstructured":"Keiser J, Manneck T, Vargas M. Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro. J Antimicrob Chemother. 2011;66:1791\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"4346_CR61","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.exppara.2010.08.011","volume":"127","author":"T Manneck","year":"2011","unstructured":"Manneck T, Braissant O, Ellis W, Keiser J. Schistosoma mansoni: antischistosomal activity of the four optical isomers and the two racemates of mefloquine on schistosomula and adult worms in vitro and in vivo. Exp Parasitol. 2011;127:260\u20139.","journal-title":"Exp Parasitol"},{"key":"4346_CR62","doi-asserted-by":"crossref","first-page":"e0003893","DOI":"10.1371\/journal.pntd.0003893","volume":"9","author":"E Yepes","year":"2015","unstructured":"Yepes E, Varela MR, Lopez-Aban J, Rojas-Caraballo J, Muro A, Mollinedo F. Inhibition of granulomatous inflammation and prophylactic treatment of schistosomiasis with a combination of edelfosine and praziquantel. PLoS Negl Trop Dis. 2015;9:e0003893.","journal-title":"PLoS Negl Trop Dis"},{"key":"4346_CR63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2017.03.005","volume":"253","author":"E Roger","year":"2017","unstructured":"Roger E, Gimel JC, Bensley C, Klymchenko AS, Benoit JP. Lipid nanocapsules maintain full integrity after crossing a human intestinal epithelium model. J Control Release. 2017;253:11\u20138.","journal-title":"J Control Release"},{"key":"4346_CR64","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.toxrep.2019.04.004","volume":"6","author":"S Ghosh","year":"2019","unstructured":"Ghosh S, Ghosh S, Sil PC. Role of nanostructures in improvising oral medicine. Toxicol Rep. 2019;6:358\u201368.","journal-title":"Toxicol Rep"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04346-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-020-04346-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04346-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T20:03:08Z","timestamp":1631649788000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-020-04346-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4346"],"URL":"https:\/\/doi.org\/10.1186\/s13071-020-04346-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.23278\/v5","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.23278\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.23278\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.23278\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.23278\/v1","asserted-by":"object"}]},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]},"assertion":[{"value":"8 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of the Faculty of Medicine, Alexandria University, based on Egyptian regulations for animal experimentation (Protocol approval number: 0201101).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"474"}}